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dysregulate mitochondrial function and stimulate
apoptosis†
Garret Rochford, a Zara Molphy, b Kevin Kavanagh, c Malachy McCann,d
Michael Devereux, a Andrew Kellett b and Orla Howe *a
Herein we report an in-depth study on the cytotoxic mechanism of action of four developmental cytotoxic
copper(II) complexes: [Cu(phen)2]
2+ (Cu-Phen); [Cu(DPQ)(Phen)]2+ (Cu-DPQ-Phen); [Cu(DPPZ)(Phen)]2+;
and [Cu(DPPN)(Phen)]2+ (where Phen = 1,10-phenanthroline, DPQ = dipyrido[3,2-f:20,30-h]quinoxaline,
DPPZ = dipyrido[3,2-a:20,30-c]phenazine, and DPPN = benzo[i]dipyrido[3,2-a:20,30-c]phenazine). This
complex class is known for its DNA intercalative properties and recent evidence—derived from an in vivo
proteomic study—supports the potential targeting of mitochondrial function. Therefore, we focused on
mitochondrial-mediated apoptosis related to cytotoxic activity and the potential impact these agents have
on mitochondrial function. The Cu(II) complexes demonstrated superior activity regardless of aromatic
extension within the phenazine ligand to the previously demonstrated activity of cisplatin. Unique toxicity
mechanisms were also identified in prior demonstrated cisplatin sensitive and resistant cell lines. Double
strand breaks in genomic DNA, quantified by gH2AX foci formation, were then coupled with apoptotic
gene expression to elucidate the mechanisms of cell death. These results indicate that while DNA damage-
induced apoptosis by BAX, XIAP and caspase-9 and -3 expression is moderate for the Cu(II) complexes
when compared to cisplatin, protein targets independent of DNA exert a multimodal mechanistic effect.
Significantly, mitochondrial gene expression of oxidative stress, protease expression, and fission/fusion
processes—upregulated HMOX, DRP1 and LON, respectively—indicated an increased oxidative damage
associated with compromised mitochondrial health upon exposure to these agents. These data support a
unique mode of action by these complexes and provide valuable evidence of the developmental potential
of these therapeutic inorganic complexes.
Significance to metallomics
The attachment of copper(II) phenanthroline to three different extended phenazine p-backbones gives novel cationic complexes multimodal biological effects.
The DNA-binding and cytotoxic properties of these complexes were probed further to show that the mitochondria are a key player in their biological effects. Our
work presents the importance of mitochondrial function and apoptotic cell death as additional mechanisms of action in their multi-modal nature.
Introduction
Copper(II) complexes are part of a large array of therapeutically
active inorganic-based small molecules.1–3 The multimodal
cellular activity of Cu(II) complexes reported in the literature includes:
association with production of reactive oxygen species,4 and knock-
on antioxidant effects, lipid peroxidation,5,6 DNA cleavage,7–9
mitochondrial dysfunction and apoptosis induction.10,11 Cu(II)
complexes with different ancillary ligands have shown strong
cytotoxicity profiles against a wide spectrum of cancer cell
lines.12–16 The Casiopeinass are a family of Cu(II) ternary
complexes that are capable of activation of apoptosis and
genotoxicity in a range of medulloblastoma, glioma and colorectal
adenocarcinoma cells.17–20 The Cu(II) complexes in this study were
synthesised and characterised by Molphy and colleagues.21,22 The
Cu(II) complexes presented in this study are Cu(II) phenanthroline
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(Cu-Phen) (1) (Fig. 1) along with their three phenazine p-backbone
extended cationic complexes Cu(II) phenanthroline–phenazine
[Cu(DPQ)(Phen)]2+ (where DPQ = dipyrido[3,2-f:20,30-h]quinoxaline)
(Cu-DPQ-Phen) (2) (Fig. 1), Cu(II) phenanthroline-phenazine
[Cu(DPPZ)(Phen)]2+ (where DPPZ = dipyrido[3,2-a:20,30-c]phena-
zine) (Cu-DPPZ-Phen) (3) (Fig. 1) and Cu(II) phenanthroline-
phenazine [Cu(DPPN)(Phen)]2+ (where DPPN = benzo[i ]dipyrido-
[3,2-a:20,30-c]phenazine) (Cu-DPPN-Phen) (4) (Fig. 1). These Cu(II)
complexes were previously biophysically characterised in addition
to a preliminary biological screening using the cisplatin resistant
SKOV-3 cell line. Both of these studies determined that the
complexes induced metal-hydroxo and free hydroxyl species and
result in 8-oxo-20-deoxyguanosine (8-oxo-dG) lesion formation.22
Additionally, the DNA binding constants of the complexes were the
highest observed in phenanthrene based complexes and were
comparable to the transcription inhibitor actinomycin D. The
preliminary biological screening demonstrated cytotoxicity in
cisplatin resistant SKOV-3 cells equivalent to adriamycin.21 A
more recent study with these complexes in the in vivo model
Galleria mellonella details a series of proteomic changes which
strongly suggest changes in antioxidant and mitochondrial
related responses.23 The in vivo study also determined that the
increased DNA binding previously established by DNA binding
studies was accompanied by increases in enzymes associated
with P450 detoxification, glycolysis, purine metabolism and nitrogen
detoxification. Interestingly, the in vivo model demonstrated that
superior nuclease action was associated with increased toxicity in the
model, while greater DNA binding increased the complexity of the
multimodal response mechanism.23 The proteomic study evidenced
substantial mitochondrial-related protein involvement in response
to the Cu(II) complexes which strongly suggested that mitochondrial-
mediated apoptosis was one of the key mechanisms of action. These
Cu(II) phenanthroline–phenazine complexes have previously demon-
strated strong DNA binding activity, therapeutic activity against
cisplatin resistant SKOV-3 cells and compelling evidence of antiox-
idant and mitochondrial-related dysfunction in G. mellonella. The
comparison of these complexes to the activity of the highly success-
ful clinical drug cisplatin is an important comparator for evaluating
the therapeutic activity of these complexes.24 The activity of these
complexes was compared to cisplatin in MCF-7 and SKOV-3 cells
lines.13,14,21 Both MCF-7 and SKOV-3 cell lines have been used in
previous studies and have demonstrated different values to those
presented in this report. A strong motivation in presenting the
isogenic A2780 cell lines along with its therapeutically resistant
daughter cell is to address the variability inherent in the use of
MCF-7 and SKOV-3 cell lines.
Based on previous studies and following from the in vivo
investigation of the activity of these Cu(II) complexes, apoptosis
and the mitochondria are a central focus of the mechanistic
investigation of these complexes in the in vitro mammalian
model. Previous studies have investigated the presence of
apoptosis as a mechanism of regulated cell death following
exposure to a range of Cu(II) complexes.11,25,26 In this study we
investigated using gene expression to examine a number of
processes in relation to the apoptotic cascade and additionally
to genes related to different functions in the mitochondria
which are key interrelated processes in apoptosis. Many proteins
are involved in the process of apoptosis (Table 1). The B cell
lymphoma-2 family (BCL-2) function in both pro- and anti-
apoptotic manners. Pro-apoptotic proteins, such as BCL-2 asso-
ciated X protein (BAX), are activated when mitochondria-mediated
apoptosis is signalled, upon which they form monomers of pores
that localize to the mitochondrial membrane so that cytochrome c
and inhibitors of X-linked Inhibitor of Apoptosis Protein (XIAP),
such as second mitochondria-derived activator of caspases (Smac)
or serine protease HTRA2/Omi, can potentiate or inhibit the
process.27 Anti-apoptotic proteins such as BCL-2 prevent this
process occurring by interacting with a BH3 regulatory repressor
protein such as Bad. Deficiencies in BCL-2 associated X protein
(BAX)/BCL-2 homologous antagonist killer (BAK) have been shown
to confer resistance in in vitro models, and over expression in
BCL-2 and B-cell Lymphoma extra-large (BCL-XL) is known to
increase resistance in vitro.28–31 Caspases are a series of serine
proteases with a pivotal role in the initiation (caspase-9) and
execution (caspase-3) of apoptosis. The caspase cascade can be
initiated in response to DNA damage and mitochondrial dys-
function in addition to other cellular stimuli.32
Multiple mitochondrial-related genes and associated signalling
events that are reported to characterise mitochondrial function were
also selected for this study (Table 1). Heme oxygenase (HMOX-1) is a
member of the phase II antioxidant enzymes and is primarily
involved in the removal of iron based porphyrin, heme from the
non-protein moiety of haemoglobin. Nuclear factor (erythroid-
derived 2)-like 2 (Nrf-2) is closely involved with the induction of
HMOX-1 through the Antioxidant Response Element (ARE) tran-
scription region.33 Nrf-2 also forms part of the transcriptional
regulation of Transcription factor B1/2, mitochondrial (TFB1M
and TFB2M) which in turn regulates the transcription of the
general mitochondrial transcription factor, Transcription Factor
A (TFAM).34–36 Genes including ATP-dependent Clp protease
proteolytic subunit (CLPP), Lon protease homolog 1 (LON1), para-
plegin matrix AAA peptidase subunit (SPG7) and ATP-dependent
Fig. 1 (A) Molecular structures of the Cu(II) phenanthroline–phenazine complexes used in this study. (B) Molecular structure of the clinical anticancer
drug cisplatin.
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metalloprotease (YME1L1) are involved in the regulation of mito-
chondrial quality control. LON and CLPP are present in the mito-
chondrial matrix and are involved in the proteolysis of oxidised
proteins from ROS damage and impaired, misfolded protein due
to damage respectively.37–39 Dynamin-Related Protein (DRP1),
Mitofusin-1/-2 (MFN1), (MFN2) and Dynamin-like 120 kDa protein
(OPA1) are involved in the control of mitochondrial fission and
fusion. The process of mitochondrial fission is largely controlled
by DRP1, which is translocated to the outer membrane of the
mitochondria to bring about fission.40 The process of mitochondrial
fusion involves OPA1 in concert with MFN1 and MFN2 which
regulate mitochondrial fusion from the inner mitochondrial
membrane and are essential for cristae remodelling, which also
has a regulatory function in oxidative phosphorylation.40,41
This study explores the mitochondrial and apoptotic
mechanisms of action of these complexes in in vitro cell models.
Materials and methods
Mammalian cell culture conditions and maintenance
The MCF-7, SKOV-3, A2780 and A2780cis cell lines were obtained
from the internal cell bank at Technological University Dublin
(TUDublin City Campus) and commercially through the European
Collection of Authenticated Cell Cultures (ECACC), Public Health
England. Each cell line was grown in Roswell Park Memorial Institute
media (RPMI-1640) (Sigma, R8758) supplemented with 12% Foetal
Bovine Serum (Sigma, F2442) and 2% L-glutamine (200 mM, Sigma,
G7513) in a T75 cell culture flask (Sigma, CLS3276). Cells cultures
were incubated at 37 1C in a 5% CO2 atmosphere. Cells were kept in
cell culture media until 80% confluent and subcultured using trypsin
solution (Thermo, 15090046) : EDTA (Sigma) (1 : 1).
Cytotoxicity assessment by MTT viability
MCF-7, SKOV-3, A2780 and A2780cis cells were subcultured and
seeded at 1  105 cells in 96-well plates and incubated for 24 h
prior to complex exposure. Cell lines were exposed to Cu-Phen
(1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen
(4). The cell lines were also treated with cisplatin (Sigma,
P4394). The Cu(II) complexes and cisplatin were dissolved in
DMSO prior to subsequent dilution with aqueous cell culture
media. Cell treatment with complexes 1–4 was performed with
an initial stock in DMSO (Sigma, 276855) (5–10 mM) prior to
dilution to a range of 0.25–10 mM with aqueous cell culture
media. The cells were treated with the Cu(II) complexes
(0.25–10 mM) and cisplatin (0.5–200 mM) for 24 h. Drug-treated
cell culture media was removed and 100 ml working solution of
MTT (methylthiazolyldiphenyl-tetrazolium bromide) (5 mg ml1)
(Sigma, M5655) was added to the cells and incubated for 3 h, as
described in the method by Mosmann, 1983.42 The cells were
washed (3) with sterile PBS (Sigma, 806544) and formazan
solubilised in 100 ml DMSO. The absorbance was recorded at
595 nm using a 1420 Multilabel Counter Victor3V spectrophoto-
meter (PerkinElmer, USA). Treatments were performed on three
separate occasions in triplicate.
Immuno-detection of cH2AX foci with flow cytometry and
confocal microscopy
A2780 and A2780cis cell lines were selected due to their
respective sensitivity and resistance to cisplatin as determined
by the MTT viability assay. Additionally, immunostaining analysis
was conducted on MCF-7 and SKOV-3 cells and data are included
in Supplementary S1 (ESI†). A2780 and A2780cis cells were
subcultured and plated at 1  105 cells in T25 flasks (Sigma,
CLS430639) and incubated for 24 h to allow for attachment and
growth. After 24 h the A2780 and A2780cis cells were exposed (at
IC25 concentration values as determined by the MTT viability
assay) to the Cu(II) complexes and cisplatin for 24 h. The cells
were fixed using 2% paraformaldehyde (Sigma, F8775) and per-
meabilised using 0.25% Triton X-100 (Sigma, T8787). The cells
were blocked using 2% Bovine Serum Albumin (Sigma, A9418) and
Table 1 Genes, their functions and associated cellular location
Gene Function Cellular location
Caspase-9 Apoptosis initiator Cytoplasm
Caspase-3 Apoptosis executioner
BCL-2 Pro- and anti-apoptotic function
BAX Pro apoptotic function, associated intrinsic apoptosis
XIAP Inhibits the activity of caspases
HMOX1 Reduces oxidative stress through catabolization of haem Mitochondria
TFAM Mitochondrial related transcription factor, associated with action of TFB1M and TFB2M
TFB1M Mitochondrial related transcription factors, associated with Nrf-2 action
TFB2M Mitochondrial related transcription factors, associated with Nrf-2 action
NRF-2 Transcription element of the ARE complex, activated through oxidative stress
CLPP
Mitochondrial protease, associated with mitochondrial quality controlLONSPG7
YME1L1
DRP1 Mitochondrial fission regulator
MFN1
Responsible for mitochondrial fusion and cristae remodellingMFN2
OPA1
Actin Assembly of microfilaments Cytoplasm (reference genes)
b-Tubulin Polymerization of microtubules
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subsequently incubated with the primary antibody, anti-phospho-
histone H2A.X (Ser 139), clone JBW301 (Cat# 05-636) (Lot#
2068177) (1 : 500) (Milipore, Ireland) and fluorescently labelled
using Alexa Fluor 488 FITC conjugate (1 : 200) (ThermoFisher,
A-11029). The cells were then washed with PBS and counterstained
using propidium iodide (1 mg ml1) (Sigma, P4864). The Median
Fluorescence Intensity (MFI) was calculated from the gated region
experimentally determined from controls using the BD Accuri C6
(BD Biosciences, USA) flow cytometer using the whole cell popula-
tion. The experimental measurements were conducted on three
separate occasions. Confocal microscopy was performed using an
LSMr 510 Meta Confocal Microscope (Zeiss, Germany) with slides
mounted in an inverted configuration. Images were recorded at
620 magnification with controls used to establish the minimum
laser gain, amplitude and offset setting in addition to identifying
the upper limits of image saturation and fluorophore excitation
using argon and helium–neon laser scanning simultaneously. All
images were analysed using ImageJ software (open source).
A2780cis images were contrast enhanced by 5% using an equalized
histogram of the image.
Apoptosis and mitochondrial-related gene expression
The molecular gene targets of apoptosis, inhibition of apoptosis
(XIAP) and mitochondrial-related function were analysed by
gene expression in real-time (Table 1). These selected candidate
genes can characterise the state of the cell specifically related to
the mitochondria after exposure to the Cu(II) phenanthroline–
phenazine complexes and cisplatin. Well-characterised cisplatin
sensitive and resistant cells were adopted to observe mechanistic
trends related to sensitivities and resistance, respectively. The
primer sequences for each gene of interest and reference gene are
presented in Table 2. Primer sequences were designed using NCBI
nucleotide sequences (https://www.ncbi.nlm.nih.gov/nucleotide/)
and Primer3PLUS and were synthesised by Sigma, Ireland.
A2780 and A2780cis cell lines were seeded at 1  104 cells in
T25 flasks and allowed 24 h to attach and grow before the cells
were treated with the complexes at their IC25 concentration
values for 24 h. Similarly, A2780 and A2780cis were treated with
cisplatin in the same manner as the Cu(II) complexes. The Cu(II)
complexes, cisplatin and untreated controls were incubated in
triplicate. The RNA extraction was performed using Tri-Reagent
(Sigma, T9424), washed in 75% ethanol and stored in 30 ml of
0.1% diethylpyrocarbonate (DEPC) treated water (Sigma,
40718). Extracted RNA was quantified using a MaestroNanot
spectrophotometer (MaestroGen, USA). Samples were normalized
to 150 ng and were converted to cDNA using the qScript cDNA
synthesis kit (Quanta Biosciences, 733-1173) employing the fol-
lowing thermal program: 5 min at 22 1C, 30 min at 42 1C, 5 min at
85 1C followed by holding at 4 1C. Synthesised cDNA templates
were amplified and quantified using SYBR Green I (Thermo,
4309155) on the 7500 Fast Real-Time PCR System (Applied
Biosystems, USA). The final reaction volume of 20 ml was ampli-
fied and quantified using the following program: (i) pre-
incubation (1 cycle) 95 1C, 5 min, ramp 4.4 1C; (ii) quantification
(45 cycles) 95 1C 10 s ramp 4.4 1C, 60 1C 10 s ramp 2.2 1C, 72 1C
10 s ramp 4.4 1C; (iii) melting curve (1 cycle) 95 1C 5 s ramp 4.4 1C,
65 1C 1 min ramp 2.2 1C, 97 1C continuous ramp 0.11 1C
acquisition 10 per 1C and (iv) cooling (1 cycle) 40 1C 10 s ramp
1.5 1C. Gene amplification of target genes was determined in
relation to the reference genes (N = 2–4). Template controls
were used to confirm the absence of autofluorescence. Relative
expression values were calculated using geometric means of the
Table 2 List of genes and oligonucleotides
Cellular region Gene Oligonucleotides (50–30) Gene Oligonucleotides (50–30)
Mitochondrial HMOX1 CAGGGCCATGAACTTTGTCC (F) TFAM GGGATCTTGCTATGTTGCCC (F)
GAGAGGGACACAGTGAGAGG (R) TTATGGTCAAGCATGGTGGC (R)
TFB1M AGTCGCCTCTCTGTTATGGC (F) TFB2M ACCAAGTAGACCTCCACACC (F)
ATGGCTGCTCTATCTTGGGC (R) GTTTTGTCACTTTCGAGCGC (R)
NRF-2 ACCAAAACCACCCTGAAAGC (F) CLPP CCTTGTTATCGCACAGCTCC (F)
AGGCCAAGTAGTGTGTCTCC (R) TCGGGTTGAGGATGTACTGC (R)
LON GAAGGAAAGTTCGTCTCGCC (F) SPG7 ATATCGAGGCCAAGGACAGG (F)
CTCATGGATCTGGGCAAACG (R) GGCCAGACGGAAAACATACC (R)
YME1L1 CTTTTCCGGAGCAGAGTTGG (F) DRP1 CCAATTATGCCAGCCAGTCC (F)
CACTTCTTCTTTCAGGCCCC (R) CTCACAATCTCGCTGTTCCC (R)
MFN1 GGAAGAGGCCAGTTTTGCC (F) MFN2 CTTGTGTGTGTCCATCTCGC (F)
GCATTTCCACCAGCTCAAGG (R) AGCATCCTTTCTACCACCCC (R)
OPA1 CCCGCTTTATGACAGAACCG (F)
GTCCTCCGCAAAGTCATTCC (R)
Cytoplasmic Casp 9 TCCAGATTGACGACAAGTGC (F) Casp 3 TTTGTTTGTGTGCTTCTGAG (F)
CCTACAAGTCGTGACAGGGA (R) TATAAGAACCGCTTTAAGT (R)
BCL-2 AAGCGGTCCCGTGGATAGA (F) BAX AGGATGCGTCCACCAAGAAG (F)
TCCGGTATTCGCAGAAGTCC (R) CCAGTTGAAGTTGCCGTCAGA (R)
XIAP GCACGGATCGTTACTTTTGGACA (F)
GTGGAAGCACTTCACTTTATCGCC (R)
Reference genes Actin ACTCTTCCAGCCTTCCTTCC (F) B-Tubulin GCTTCTTGGTTTTCCACAGC (F)
GTTGGCGTACAGGTCTTTGC (R) CGTTCTTCAGGTTCGACCTC (R)
Highlighted in bold are the primers of reference genes used to establish the relative expression of the target genes. (F) refers to forward primer
while (R) refers to reverse primer.
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reference genes and target genes were normalized according to
the Livak and Schmittgen formula: 2DCt1(test)DCt2(control).43
Statistical analysis
The MTT assay raw data were normalized to the negative
control within each experiment. The statistical package, Prism
(ver. 5.0) (GraphPad, USA) was used to establish the 25%
inhibitory concentration (IC25) using least squares non-linear
regression analysis. The statistical significance of the changes
between treatment with the Cu(II) complexes and the cisplatin
was determined using one-way ANOVA with Tukey’s post hoc
test. The flow cytometry data analysis was performed using the
BD Accuri C6 software package and Microsofts Excel (USA) to
establish the mean of the MFI and percent positive data. Prism
was used to perform one-way ANOVA significance testing with
post hoc Bonferroni correction between test complexes and the
control. For the analysis of gene expression, the geometric
mean Ct values for both actin and tubulin reference genes were
used for normalization as per the Vandesompele method.44
Target gene expression values were calculated along with a
standard deviation as per the Nordgård, Livak and Schmittgen
formula.43,45 Both the positive and negative error bars display
the 95% confidence interval around the mean normalized gene
expression value.
Results
Cytotoxicity assessment by MTT viability
The MTT assay was used to establish the activity of Cu-Phen (1),
Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) in
both cisplatin-sensitive (MCF-7 and A2780) (Table 3) and
cisplatin-resistant (SKOV-3, A2780cis) cells relative to the established
clinical therapeutic; cisplatin (Table 3). Cisplatin was tested over the
concentration range of 0.5–200 mM and Cu-Phen (1), Cu-DPQ-Phen
(2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) were tested over
0.25–10 mM. Cisplatin displayed a varied level of activity across
the range of tested cell lines with SKOV-3 cells presenting the
indicative profile of platinum resistance.46 Cisplatin displayed
differential activity in both A2780 and A2780cis cell lines, with
the resistant variant demonstrating a higher concentration in
relation to the sensitive variant at 24 h (4200 mM and 63.10 mM,
respectively). The Cu(II) complexes (1–4) all showed IC25 values
of o10 mM. The A2780 and the cisplatin-resistant counterpart
A2780cis demonstrate classic cisplatin resistance, whereas
SKOV-3 cells demonstrate cisplatin resistance but to a lower
extent. The diminished level of cisplatin resistance observed in
SKOV-3 cells has previously been documented in the evaluation
of other novel Cu complexes.12,14,16 Cu(II) phenanthroline phenazine
complexes demonstrate superior activity (as denoted by *) to
cisplatin in all cell lines while the cisplatin sensitive cell lines
(MCF-7 and A2780) demonstrate higher toxicity towards the
Cu(II) complexes in comparison to both known cisplatin resistant
cell lines (SKOV-3 and A2780cis). Exposure to Cu(II) phenanthroline–
phenazine complexes demonstrated consistently increased toxicities
irrespective of the ligated phenazine structure in comparison to
cisplatin with Cu-DPPN-Phen (4) showing slightly lower toxicity
possible due to larger size and lipophilicity. Overall the inclusion
of cisplatin resistant cell lines demonstrates that cisplatin
resistance is not a confounding factor for the activity of the
Cu(II) phenanthroline–phenazine complexes.
Immunodetection of cH2AX foci with flow cytometry and
confocal microscopy
The induction of gH2AX foci was detected using flow cytometry
and confocal microscopy after A2780 and A2780cis cells were
exposed to the IC25 concentrations of cisplatin and the Cu(II)
phenanthroline–phenazine complexes for 24 h and compared
to the unexposed control. Foci formation was determined using
MFI (Fig. 2).
Following the exposure of A2780 to cisplatin and the Cu(II)
complexes, a significant increase (p r 0.05) in foci formation
was observed, with the exception of Cu-DPPN-Phen (4). Induction
of gH2AX foci in A2780 cells occurred to a small extent after
exposure to Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3)
and is absent upon treatment with Cu-DPPN-Phen (4). The
induction of gH2AX foci in the A2780cis cells occurs to a larger
extent following exposure to Cu-Phen (1) and Cu-DPQ-Phen (2)
and is almost entirely absent after exposure to Cu-DPPZ-Phen
(3) and Cu-DPPN-Phen (4). The exposure of A2780cis cells to
cisplatin induces non-significant variable increases in foci
formation. The induction of gH2AX foci was also detected
using confocal microscopy imaging to record the incidences
of foci formation using the FITC labelled antibody and the
nuclear counterstain, propidium iodide (Fig. 3). Overall, the
results of confocal microscopy complement the flow cytometry
results.
Table 3 IC25 values for MCF-7, A2780, SKOV-3 and A2780cis cells over 24 h drug exposure
Treatment
IC25 (mM)  S.D.
Cisplatin-sensitive Cisplatin-resistant
MCF-7 A2780 SKOV-3 A2780cis
Cisplatin 0.45  0.07 63.10  13.91 21.52  4.54 4200
Cu-Phen (1) 0.97  0.10 0.39  0.07*** 2.56  0.12*** 0.83  0.00***
Cu-DPQ-Phen (2) 1.27  0.40* 0.34  0.09*** 2.51  0.09*** 0.72  0.02***
Cu-DPPZ-Phen (3) 0.63  0.01 0.31  0.04*** 1.61  0.74*** 0.39  0.07***
Cu-DPPN-Phen (4) 1.37  0.32** 0.36  0.10*** 5.71  0.92*** 0.53  0.02***
Mean  standard deviation (N = 3). * denotes p o 0.05 in comparison to cisplatin. ** denotes p o 0.01 in comparison to cisplatin. *** denotes p o
0.001 in comparison to cisplatin.
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Apoptosis and mitochondrial-related gene expression
The level of gene expression in the target genes was represented
in relation to the geometric mean of the reference genes. The
variance for target genes was error propagated and log(2)
transformed and a 95% confidence interval was plotted around
the DDCt value. Grouped columns in Fig. 4–6 display the log(2)
transformed mean expression value relative to the biological
negative control, with the broken line at y = 1 indicating lower
expression below and higher expression above.
Differential expression of Bax and XIAP expression was
observed between A2780 (Fig. 4A) and A2780cis cells (Fig. 4B)
when each was exposed to cisplatin. The increase in expression
of BCL-2, an anti-apoptotic gene in A2780cis cells, demonstrated
a classic mechanism of cisplatin resistance. The apoptotic
response following exposure to the Cu(II) complex was markedly
different to that of cisplatin. The apoptotic response to the Cu(II)
complexes is characterised by increase of BAX and with markedly
increased expression in the anti-apoptotic gene, XIAP. Caspase 9,
caspase 3, BCL-2 and BAX characterise the response to the Cu(II)
complexes, and particularly to exposure to Cu-DPPZ-Phen (3) and
Cu-DPPN-Phen (4) in the cisplatin-resistant A2780cis cells. The
differential apoptotic response between the Cu(II) complexes and
cisplatin in the A2780cis resistant cells demonstrates that the
cisplatin resistance is not an impeding factor in the activity of the
Cu(II) complexes.
The mitochondrial related gene expression profile produced
by the A2780 cells (Fig. 5) demonstrates that the mitochondrial
protease gene, CLPP and to a smaller extent the mitochondrial
fusion gene, OPA1 are elevated following exposure to cisplatin.
This profile is in contrast to that caused by exposure to Cu-Phen (1)
where only a small increase in the oxidative stress, transcription,
protease and fission/fusion genes was detected. All of the other
Cu(II) complexes produce no significant increase except for a
strong increase in the mitochondrial fission regulator, OPA1 after
exposure to Cu-DPPN-Phen (4). The gene expression profile in the
A2780cis cells (Fig. 6) showed significant changes in comparison to
the A2780 cells. Cisplatin action features prominently in the
mitochondrial fission/fusion regulation in the resistant cells in
contrast to the sensitive A2780 cells. In contrast to A2780 cells,
exposing A2780cis cells to the Cu(II) complexes produced sub-
stantial increases in oxidative stress, transcription, protease
and fission/fusion genes. An increase was observed in oxidative
stress/transcription and protease genes after exposure of
A2780cis cells to Cu-DPQ-Phen (2), which contrasts with the
response of the A2780 cells. Considerable increases in the gene
groups in A2780cis cells was recorded following treatment with
Cu-DPPN-Phen (4), which again differs to the behaviour of the
A2780 cells. In contrast to the performance of the A2780 cells, the
DRP1 fission regulator has increased expression after exposing
the resistant cells to cisplatin and the Cu(II) complexes, demon-
strating a similar therapeutic response to both types of
metal complex. The use of the cisplatin-resistant A2780cis cells
Fig. 3 Confocal microscopy images of gH2AX foci (indicated by yellow arrow and circle) arising from treatment of A2780 and A2780cis cells with
cisplatin and the Cu(II) complexes. Red staining indicates nuclear material with green foci representing double stranded DNA break formation (gH2AX).
Fig. 2 Immunodetection using MFI of gH2AX foci in A2780 and A2780cis
cells after 24 h treatment with cisplatin and the Cu(II) complexes. Statistical
significance was determined between the negative control and the Cu(II)
complexes using one-way ANOVA with Bonferroni correction.
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demonstrates that the Cu(II) complexes operate through a
different mechanistic mode of action to cisplatin and, furthermore,
the Cu(II) complexes have substantially different mechanism(s)
of action against cisplatin-resistant cells compared to the
cisplatin-sensitive phenotype.
Discussion
Having recently established, the multimodal effects against the
in vivo model, G. mellonella in a proteomic study,23 and the
previously reported oxidative chemical nuclease and DNA binding
properties of the Cu(II) phenanthroline–phenazine complexes,21,22
the aim of this study was to use in vitro models to investigate the
mechanism(s) of action of these complexes. Cancer cell lines that
confer sensitivity and resistance to the clinical drug, cisplatin, were
used so that the mechanisms could be contrasted to cisplatin.
Both the MCF-7 (breast) and SKOV-3 (ovarian) cells have been cited
in the literature as cisplatin-sensitive and -resistant cell lines,
respectively, and are part of the NCI developmental therapeutics
program.47–53 Additionally, the use of MCF-7 and SKOV-3 cell lines
previously,13,14,21 demonstrated the variable nature of the response
to cisplatin in cells derived from different tissues. The A2780
(ovarian) cell line represents the parental lineage of a number
of daughter cell lines, which are made resistant to various
therapeutics such as doxorubicin (A2780ADR) and cross-resistant
to melphalan, doxorubicin and cisplatin (A2780cis). The gen-
eration of resistant profiles in the A2780 parent cell lines is
brought about through the supplementation of sub-toxic dose
of the drug in question in the culture media in order to confer
resistance over multiple passages of the cell. While MCF-7 and
SKOV-3 cells have previously demonstrated cisplatin-sensitive
Fig. 4 A/B Gene expression by A2780 and A2780cis cells following treatment with cisplatin and the Cu(II) complexes. Error bars represent normalized
standard deviation. Values below y = 1 (dotted line) represent negative expression. Target genes normalized to the geometric mean of actin and tubulin.
N.D. = not detected.
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and -resistant profiles respectively,13,14 the direct comparison
between the cell types is limited by their different tissue of
origin and subsequently differing gene and protein expression
profile. The A2780 and A2780cis cisplatin-resistant daughter
cells have transcriptional and protein expression profiles that
are comparative, and have been employed in multiple studies
examining ovarian cancer and the biological mechanisms
that contribute to therapeutic resistance.48–53 The use of the
isogenic A2780 parent and resistant A2780cis phenotype has
gained popularity as a more homogeneous platform where
sub-toxic levels of cisplatin are added to the culture media of
A2780cis cells to generate and retain the resistance profile.54
Fig. 5 Gene expression by A2780 cells after 24 h exposure to cisplatin and the Cu(II) complexes. Error bars represent normalized standard deviation.
Values below y = 1 (dotted line) represent negative expression. Target genes normalized to the geometric mean of actin and tubulin.
Fig. 6 Gene expression by A2780cis cells after 24 h exposure to cisplatin and the Cu(II) complexes. Error bars represent normalized standard deviation.
Values below y = 1 (dotted line) represent negative expression. Target genes normalized to the geometric mean of actin and tubulin. N.D. = not detected.
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These cells were used to compare the biological effects of the
Cu(II) complexes and cisplatin on the MCF-7 and SKOV-3
traditional cells to the effects on the A2780 and A2780cis cells.
Overall, the cytotoxicity profile of the Cu(II) phenanthroline–
phenazine complexes demonstrated a cytotoxicity profile with
the following cadence Cu-DPPZ-Phen (3) (most toxic) 4
Cu-Phen (1) B Cu-DPQ-Phen (2) 4 Cu-DPPN-Phen (4) (least
toxic). Superior cytotoxicity activity of the Cu(II) phenanthro-
line–phenazine complexes to the clinical control, cisplatin, was
noted in the cisplatin-resistant cell line (A2780cis). A previous
study by Molphy et al. established a similar cytotoxic profile
against the SKOV-3 cell line which accompanied the highest
DNA binding constants and was also comparable to the oxidative
DNA damaging agent doxorubicin.21 The development of DNA
damage is a key hallmark of cisplatin cytotoxicity and, as such,
has been a valuable indicator in the profiling of new therapeutics.
gH2AX foci formation is indicative of double stranded breaks
(DSBs) in the DNA, and the induction of DSBs by the current
Cu(II) complexes was observed. The MCF-7 and A2780 cell lines
had less DSBs, which might indicate an alternative mode of
action in the resistant cell lines. Additionally, the high levels of
DSBs in SKOV-3 and A2780cis cells may be the driver of higher
cytotoxicity of the Cu(II) complexes compared to cisplatin, this
being despite the development of resistance to cisplatin-induced
DNA damage by these two cell lines. This strongly suggests
that the Cu(II) complexes are operating through biochemical
mechanisms that are distinctly different to those of cisplatin.
The identification of alternative mechanisms of action to
cisplatin is indeed a developmental objective in metal-based
anticancer chemotherapy. Recently our in vivo study in G. mellonella
demonstrated increased levels of glutathione S-transferase (GST) in
larvae exposed to the Cu(II) complexes.23 The Cu(II) complexes
contain polycyclic aromatic rings which have a similar cyclical
structure to the DNA damaging agents naphthalene and benzo-
[a]-pyrene. Additionally, GST is also upregulated in cells exposed
to the chemical nuclease activity of cyclophosphamide and
ifosfamide. The generation of oxidative radicals is a key mecha-
nism through which DNA damage occurs. Due to the previously
demonstrated nuclease cleavage ability of these Cu(II) complexes22
and structural similarity to the intercalating ruthenium complex
L-[Ru (phen)2dppz]
2+,55 it is likely that the Cu(II) complexes inter-
calate with the DNA in a similar fashion in addition to the nuclease
capability of the complex facilitating DNA strand breakage. The
G. mellonella study also determined that enzymes regulating purine
synthesis were upregulated along with heat shock protein 90 which
are present during increased purine turnover and the formation of
the purinosome.56 The high degree of cytotoxicity in SKOV-3 and
A2780cis prompted further investigation of apoptosis, which is one
of the most important mechanisms of regulated cell death.
Apoptotic cell death is related to loss in cellular viability
accompanied by cytotoxicity.27 Transition metal coordinated
therapeutics have often been evaluated for their ability to
induce apoptosis and other forms of regulated cell death with
many evaluative studies on copper complexes using this as a
therapeutic endpoint.25,26,57–62 Additionally, cisplatin and other
therapeutic compounds have been evaluated for their direct
activity against BCL-2.30,63 While these studies have used
different markers of apoptosis to demonstrate the induction
of this endpoint, the use of gene expression in this study allows
multiple pathways in the apoptotic process to be investigated.
Mitochondrial-mediated apoptosis can be initiated by the
induction of DNA damage through p53 or the action of Bax
and BCL-2 regulated by BH3 proteins of the BCL2 family. The
upregulation of BCL-2 was observed in the cisplatin-resistant
cell lines which is seen as a classic form of drug resistance.64,65
This pattern was in direct contrast to that found when the cells
were exposed to the Cu(II) complexes, where increased levels of
BAX and XIAP were detected. Additionally, caspase-9 and
caspase-3 genes were also expressed with the Cu(II) complexes,
indicating a complete apoptotic cascade. The upregulation of
BAX is a key progenitor of the formation of the mitochondrial
outer membrane pores (MOMP) in mitochondria which then
induces the caspase cascade (caspase-9 and caspase-3) for
apoptosis.66 The mitochondria are being increasingly recog-
nised as a focal point for a multiple cellular process which
proves pivotal in directing the fate of the cell. Critical amongst
these are responses to inflammation,67,68 ROS,69–73 and
apoptosis,72,74–76 which are closely associated and dependent
on the mitochondria. Indeed, substantial effort is being directed
towards developing therapeutic targets in the mitochondria or
processes associated with its action.77–80
The high toxicity profiles of the Cu(II) complexes with
moderate to low in vitro DNA damage recorded by gH2AX foci
coupled with mitochondrial-mediated pro-apoptotic gene expression
led to further interest in the role and activity of the mitochondria
beyond apoptosis. The mitochondrial related gene expression panel
was examined through antioxidant enzyme production, HMOX
(Table 1), while mitochondrial related transcription was
monitored through TFAM, TFB1M, TFB2M and NRF-2 (Table 1).
Mitochondrial protease genes were monitored through CLPP,
LON, SPG7 and YME1L1 (Table 1). The process of fission/fusion
of the mitochondria was examined through DRP1, MFN1, MFN2
and OPA1 (Table 1). The groups of genes representing the
mitochondrial, antioxidant, transcription and protease functions
demonstrated the highest changes in expression between A2780
and A2780cis resistant cells. Exposure of resistant A2780cis cells
to cisplatin induces a characteristic resistance to mitophagy through
upregulation of DRP1 and mitochondrial related transcription
factors.81,82 The role of DRP1 in mitochondrial remodelling and its
relationship to apoptosis has become clearer over the past few years.
While DRP1 is involved in mitochondrial membrane impairment
and uncoupling of oxidative phosphorylation leading to its identifi-
cation as a drug resistance factor,83,84 new information has emerged
about its direct role in bringing about apoptosis through accelerating
cytochrome c release from the mitochondrial membrane,85 and
additional functions in the responses to oxidative stress,86 and
cellular differentiation.87–89 The activity of the mitochondrial-
related transcription factors and the fission/fusion regulator are
also known to be involved in the drug resistance response.84,90–92
As determined above, the differences in apoptosis between the
Cu(II) complexes and cisplatin centre around the activation of
BAX and XIAP, caspase-9 and caspase-3. In contrast to this, the
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mitochondria fission regulator, DRP1, is commonly upregulated
in all exposures. The upregulation of DRP1 has recently been
associated with cisplatin resistance81,82,93–95 and apoptosis through
cytochrome c release,85 and with a similar upregulation after
exposure to the Cu(II) complexes this may indicate the exploitation
of a similar mechanism of action. While similarities in mechanisms
can be shown with DRP1 activity, the upregulation of all proteases
particularly LON, following exposure of A2780cis cells to the
Cu(II) complexes may indicate an increased rate of protein
turnover due to misfolded, oxidized and otherwise denatured
proteins, which may be contributing to the enhanced cytotoxi-
city of the Cu(II) complexes.96–98 Additionally, the presence of
HMOX and transcription factors related to the antioxidant
response in the A2780cis cells treated with the Cu(II) complexes,
builds on the evidence of upregulated protease factors to demon-
strate potential increases in protein dysregulation as a potent
factor in the mitochondrial toxicity.36,99 Previously our in vivo
G. mellonella study demonstrated increases in protein expression
of metabolic enzymes associated with the mitochondria.23 These
changes also accompanied increase in pathways associated with
protein detoxification and degradation, which complements
the gene expression activity observed in this study indicating
increased protein turnover potentially due to oxidative damage
from mitochondrial dysregulation or the direct action of the
Cu(II) complexes.
These Cu(II) complexes have a unique profile of cytotoxicity
differing from that of cisplatin. The investigation into the
effects of the mitochondria using gene expression has provided
a wider context to the mechanistic activity in addition to demon-
strating apoptosis. The results presented here demonstrate that
Cu(II) phenanthroline–phenazine complexes are a promising
therapeutic candidate which are highly potent against cisplatin-
resistant cells. The superior activity, together with their multi-
modal activity against cisplatin-resistant cells offers a potentially
novel therapeutic avenue for treating cisplatin-refractory cancers
in combination with current chemotherapy.
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M. Hatzoglou, O. Bussolati and R. Franchi-Gazzola, The
Thioxotriazole Copper(II) Complex A0 Induces Endoplasmic
Reticulum Stress and Paraptotic Death in Human Cancer
Cells, J. Biol. Chem., 2009, 284, 24306–24319.
60 J. Qi, S. Liang, Y. Gou, Z. Zhang, Z. Zhou, F. Yang and
H. Liang, Synthesis of Four Binuclear Copper(II) Complexes:
Structure, Anticancer Properties and Anticancer Mechanism,
Eur. J. Med. Chem., 2015, 96, 360–368.
Paper Metallomics
This journal is©The Royal Society of Chemistry 2020 Metallomics, 2020, 12, 65--78 | 77
61 C. Caruso Bavisotto, D. Nikolic, A. Marino Gammazza,
R. Barone, F. Lo Cascio, E. Mocciaro, G. Zummo, E. Conway
De Macario, A. J. Macario, F. Cappello, V. Giacalone, A. Pace,
G. Barone, A. P. Piccionello and C. Campanella, The Dissociation
of the Hsp60/pro-Caspase-3 Complex by Bis(Pyridyl)Oxadiazole
Copper Complex (CubipyOXA) Leads to Cell Death in NCI-H292
Cancer Cells, J. Inorg. Biochem., 2017, 170, 8–16.
62 B. Thati, A. Noble, B. S. Creaven, M. Walsh, K. Kavanagh
and D. A. Egan, Apoptotic Cell Death: A Possible Key Event
in Mediating the in Vitro Anti-Proliferative Effect of a Novel
Copper(II) Complex, [Cu(4-Mecdoa)(Phen)(2)] (Phen = phenan-
throline, 4-Mecdoa = 4-Methylcoumarin-6,7-Dioxactetate), in
Human Malignant Cancer Cells, Eur. J. Pharmacol., 2007, 168,
16–28.
63 K. J. Campbell and S. W. G. Tait, Targeting BCL-2 Regulated
Apoptosis in Cancer, Open Biol., 2018, 8, 180002, DOI:
10.1098/rsob.180002.
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